Drug Profile
FFP 102
Alternative Names: FFP102; PG-102; PG102-prototypeLatest Information Update: 30 Sep 2015
Price :
$50
*
At a glance
- Originator PanGenetics BV
- Developer FF Pharma; PanGenetics BV
- Class Monoclonal antibodies
- Mechanism of Action CD40 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Crohn's disease
- Discontinued Psoriatic arthritis
Most Recent Events
- 30 Sep 2015 Clinical development of FFP 102 is ongoing in the Netherlands
- 11 Jul 2013 FFP 102 is still in phase I/II trials for Crohn's disease in the Netherlands
- 23 Jan 2013 PG 102 licensed to FF Pharmaceuticals